Compare HNVR & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | LENZ |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 142.0M |
| IPO Year | 2022 | 2021 |
| Metric | HNVR | LENZ |
|---|---|---|
| Price | $26.43 | $4.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $24.50 | ★ $44.00 |
| AVG Volume (30 Days) | 29.2K | ★ 624.3K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | $35.49 | $50.42 |
| Revenue Next Year | $8.61 | $197.16 |
| P/E Ratio | $33.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $4.01 |
| 52 Week High | $27.94 | $50.19 |
| Indicator | HNVR | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 32.77 |
| Support Level | $26.41 | N/A |
| Resistance Level | $27.89 | $6.11 |
| Average True Range (ATR) | 0.70 | 0.32 |
| MACD | -0.13 | -0.11 |
| Stochastic Oscillator | 15.79 | 4.06 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.